SRC and diabetes mellitus: Recent studies in other disease models suggest that inhibition of Src-dependent EGFR transactivation by Ang-(1–7) may be a general mechanism of action of this heptapeptide (Kilarkaje et al., 2013; Yousif et al., 2014; El-Hashim et al., 2019) and may represent an important mechanism by which it may exert its beneficial effects in diabetes-induced vascular complications.